Original InvestigationBivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial
Under an Elsevier user license
open archive
Key Words
anticoagulation
bivalirudin
major bleeding
transcatheter aortic valve replacement
Abbreviations and Acronyms
BARC
Bleeding Academic Research Consortium
CI
confidence interval
TAVR
transcatheter aortic valve replacement
Cited by (0)
Supported by The Medicines Company. Drs. Dangas, Mehran, and Fach have received grants from The Medicines Company (modest level). Dr. ten Berg has received personal fees from The Medicines Company. Dr. Windecker has received research grants (to the institution) from The Medicines Company. Drs. Anthopoulos, Bernstein, Deliargyris, and Wijngaard and Mrs. Lechthaler are employees of The Medicines Company. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Deepak Bhatt, MD, served as Guest Editor for this paper.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.